Compare WULF & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WULF | ACLX |
|---|---|---|
| Founded | 1952 | 2015 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 4.2B |
| IPO Year | 1995 | 2022 |
| Metric | WULF | ACLX |
|---|---|---|
| Price | $14.50 | $69.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $16.71 | ★ $115.50 |
| AVG Volume (30 Days) | ★ 42.6M | 1.2M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $167,604,000.00 | $35,898,000.00 |
| Revenue This Year | $33.36 | N/A |
| Revenue Next Year | $124.75 | $302.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.58 | N/A |
| 52 Week Low | $2.06 | $47.86 |
| 52 Week High | $17.05 | $94.07 |
| Indicator | WULF | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 33.01 |
| Support Level | $13.43 | $66.00 |
| Resistance Level | $15.22 | $75.03 |
| Average True Range (ATR) | 1.40 | 5.23 |
| MACD | 0.20 | -1.69 |
| Stochastic Oscillator | 71.20 | 12.96 |
TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.